Italfarmaco Spa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ITALFARMACO SPA, and when can generic versions of ITALFARMACO SPA drugs launch?
ITALFARMACO SPA has one approved drug.
There are four US patents protecting ITALFARMACO SPA drugs.
There are fifty-three patent family members on ITALFARMACO SPA drugs in twenty-nine countries.
Summary for Italfarmaco Spa
International Patents: | 53 |
US Patents: | 4 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 1 |
Drugs and US Patents for Italfarmaco Spa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Italfarmaco Spa | DUVYZAT | givinostat hydrochloride | SUSPENSION;ORAL | 217865-001 | Mar 21, 2024 | RX | Yes | Yes | 7,329,689 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Italfarmaco Spa | DUVYZAT | givinostat hydrochloride | SUSPENSION;ORAL | 217865-001 | Mar 21, 2024 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Italfarmaco Spa | DUVYZAT | givinostat hydrochloride | SUSPENSION;ORAL | 217865-001 | Mar 21, 2024 | RX | Yes | Yes | 9,421,184 | ⤷ Subscribe | ⤷ Subscribe | ||||
Italfarmaco Spa | DUVYZAT | givinostat hydrochloride | SUSPENSION;ORAL | 217865-001 | Mar 21, 2024 | RX | Yes | Yes | 10,688,047 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Italfarmaco Spa Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Cyprus | 1124092 | ⤷ Subscribe |
Japan | 2016128504 | ⤷ Subscribe |
Mexico | 370451 | ⤷ Subscribe |
Colombia | 2018003971 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.